Ready to sell your novel device in the United States? In a system based on predicate devices and substantial equivalence, marketing an innovative or novel device comes with some unique challenges. What do you do when your innovative device has no predicate?
As the range of novel and innovative medical devices continues to grow, the challenge for both industry and the US FDA is to determine the best way to get these new devices to health care providers and patients as soon as possible, while ensuring safety and effectiveness. In this whitepaper, we discuss your options for bringing your novel device to the US market.
What you will learn in this 7-page white paper:
Get answers to all of these questions and more in this white paper.
Audrey Swearingen, RAC (US): Audrey Swearingen is Director of Regulatory Affairs at Emergo's Austin, Texas headquarters. With over 20 years of experience in regulatory affairs, Audrey's areas of expertise include US FDA medical device registration, as well as European and Canadian device registration.
自2018年起,美国食品和药物管理局(U.S. Food and Drug Administration,FDA)开始试行以电子化方式来帮助行业提供完整的510(k)上市前通知。2022年,为推进以电子格式提供510(k)递交文件的过渡,美国FDA正式发布关于使用电子递交模板和资源的最终指导文
阅读更多新欧盟体外诊断器械法规(IVDR,In Vitro Diagnostic Device Regulation (EU) 2017/746)IVDR的发布为体外诊断器械医疗器械制造商满足欧洲市场合规带来新规实施、新旧过渡的诸多前所未有的挑战。对此,全球医疗器械及IVD器械合规专家Emergo b
阅读更多